Blastoid and pleomorphic mantle cell lymphoma: still a diagnostic and therapeutic challenge!

Abstract

Blastoid mantle cell lymphoma is characterized by highly aggressive features and a dismal clinical course. These blastoid and pleomorphic variants are defined by cytomorphological features, but the criteria are somewhat subjective. The diagnosis may be supported by a high cell proliferation based on the Ki-67 labeling index. Recent analyses have shown that the Ki-67 index overrules the prognostic information derived from the cytology subtypes. Nevertheless, genetic analysis suggests that blastoid and pleomorphic variants are distinct from classical mantle cell lymphoma. In clinical cohorts, the frequency of these subsets varies widely but probably represents ∼10% of all cases. Chemotherapy regimens commonly used in mantle cell lymphoma, such as bendamustine, rarely achieve prolonged remissions when given at the dosage developed for classical variants of the disease. Thus, high-dose cytarabine-containing regimens with high-dose consolidation may be generally recommended based on the more aggressive clinical course in these patients. However, even with these intensified regimens, the long-term outcome seems to be impaired. Thus, especially in this patient subset, allogeneic transplantation may be discussed at an early time point in disease management. Accordingly, targeted approaches are warranted in these patients, but clinical data are scarce. Ibrutinib treatment results in high rates of responses, but the median duration of remission is <6 months. Similarly, lenalidomide and temsirolimus result in only short-term remissions. Novel approaches, such as chimeric antigenic receptor T cells, may have the potential to finally improve the dismal long-term outcome of these patients.

• Authors: Martin Dreyling, Wolfram Klapper, Simon Rule
• Journal: Blood (Blood) Vol. 132 Issue 26 Pg. 2722-2729 (12 27 2018) ISSN: 1528-0020 [Electronic] United States
• PMID: 30385481 (Publication Type: Journal Article, Review)
• Copyright: © 2018 by The American Society of Hematology.

Chemical References

• Antineoplastic Agents
• Ki-67 Antigen

Topics

• Aged
• Antineoplastic Agents (therapeutic use)
• Cell Proliferation
• Female
• Humans
• Ki-67 Antigen (metabolism)
• Lymphoma, Mantle-Cell (diagnosis, drug therapy, metabolism, pathology)
• Middle Aged
• Prognosis